124, Ms

Technische Daten
Zelluläre Lokalisation:Cytoplasmic
Vorbehandlung:ProTaqs® Antigen Enhancer I (Cat. No. 401602092) or ProTaqs® Antigen Enhancer IV (Cat. No. 401602392)
Immunogen:BCL2 protein
Ig Unterklasse:IgG1/k
Status:In Vitro Diagnostic Use (IVD)
Change(s) made:Complete revision
Synonyme:B cell lymphoma 2/Bcl2
Verfügbar in folgenden Ländern:worldwide

Bcl-2 (B-cell lymphoma 2) plays an important role in regulation of apoptosis. It is expressed in different cells and tissues. Overexpression due to chromosomal translocation, gene amplification, increased gene transcription and/or altered post-translational processing is found in many cancer types. These include B-cell malignancies, such as B-cell lymphoma, follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL), as well as some T-cell lymphomas, breast cancer, lung cancer, ovarian cancer, and prostata cancer.


[1] Hata AN, Engelman JA and Faber AC (2015): The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics. Cancer Discov. 5(5):475-87.
[2] Anderson MA, Huang D and Roberts A (2014): Targeting BCL2 for the treatment of lymphoid malignancies. Semin Hematol. 51(3):219-27.
[3] Vogler M (2014): Targeting BCL2-Proteins for the Treatment of Solid Tumours. Adv Med. 2014:943648.